Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization Hiroshi Kumano, MD, PhD, Shigefumi Suehiro, MD, PhD, Koji.

Slides:

Advertisements

Similar presentations

The effect of cardiotomy suction on the brain injury marker S100β after cardiopulmonary bypass Russell E Anderson, MD, PhD, Lars-Olof Hansson, MD, PhD,

Advertisements

Stress-Dose Corticosteroid Versus Placebo in Neonatal Cardiac Operations: A Randomized Controlled Trial Pertti K. Suominen, MD, PhD, Juho Keski-Nisula,

Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent.

Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration Jean-Olivier Defraigne, MD, PhD,

Blood coagulation and fibrinolytic response after endovascular stent grafting of thoracic aorta1 Taro Shimazaki, MD, Shin Ishimaru, MD, Satoshi Kawaguchi,

Attenuation of Changes in Leukocyte Surface Markers and Complement Activation With Heparin-Coated Cardiopulmonary Bypass Oddvar Moen, MD, Kolbjørn Høgåsen,

A Closed Perfusion System With Heparin Coating and Centrifugal Pump Improves Cardiopulmonary Bypass Biocompatibility in Elderly Patients Lena Lindholm,

Thomas V Bilfinger, MD, George B Stefano, PhD

Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study Song Wan, MD, PhD, Jean-Louis.

Clinical implication of plasma level of soluble fibrin monomer-fibrinogen complex in patients with abdominal aortic aneurysm Akihiro Hosaka, MD, Tetsuro.

Reduction of heparin dose is not beneficial to platelet function

P. W. Boonstra, MD, PhD, Y. J. Gu, MD, PhD, C. Akkerman, BSc, J

Alterations in coagulation after implantation of a pulsatile Novacor LVAD and the axial flow micromed DeBakey LVAD Andreas Koster, MD, Matthias Loebe,

Prospective, Randomized, Double-Blind Study of High-Dose Aprotinin in Pediatric Cardiac Operations Michael J Davies, FRCS, Alison Allen, BScHons, Henry.

Bashir M Matata, PhD, Andrzej W Sosnowski, MD, Manuel Galiñanes

Assessment of heparin anticoagulation: comparison of two commercially available methods Hanne I Flom-Halvorsen, PhD, Eivind Øvrum, MD, PhD, Michel Abdelnoor,

Repair of Postinfarction Ventricular Septal Defect With Joined Endocardial Patches Toshihiko Shibata, MD, Shigefumi Suehiro, MD, PhD, Takumi Ishikawa,

How safe is the port access technique in minimally invasive coronary artery bypass grafting? Selami Dogan, MD, Kai Graubitz, MD, Tayfun Aybek, MD, Mohammad.

Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only Thierry P Carrel, MD, Mike Schwanda, MD,

Susanne Lison, MD, Michael Spannagl, MD, PhD, Wulf Dietrich, MD, PhD

Hedi H Schreurs, Marianne J Wijers, Y

An Analysis of Oxygen Consumption and Oxygen Delivery in Euthermic Infants After Cardiopulmonary Bypass With Modified Ultrafiltration Jia Li, MD, PhD,

Effect of Heparin Loading During Congenital Heart Operation on Thrombin Generation and Blood Loss Sophronia O Turner-Gomes, MB, ChB, Evan P Nitschmann,

Human cytokine responses to coronary artery bypass grafting with and without cardiopulmonary bypass Martin Strüber, MD, Jochen T Cremer, MD, Bernhard.

Managing Fibrinolysis Without Aprotinin

Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass Alvise Bernabei,

Comparative effects of propofol versus fentanyl on cerebral oxygenation state during normothermic cardiopulmonary bypass and postoperative cognitive dysfunction

Stress-Dose Corticosteroid Versus Placebo in Neonatal Cardiac Operations: A Randomized Controlled Trial Pertti K. Suominen, MD, PhD, Juho Keski-Nisula,

John S. Ikonomidis, MD, PhD, Ebony J

Outcome After the Modified Bentall Technique With a Long Interposed Graft to the Left Coronary Artery Atsushi Nakahira, MD, Toshihiko Shibata, MD, PhD,

Anne H Kuitunen, MD, Lasse J Heikkilä, MD, Markku T Salmenperä, MD

Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model Hitoshi Suhara, MD, Yoshiki Sawa, MD, Motonobu Nishimura,

Coronary surgery without cardiotomy suction and autotransfusion reduces the postoperative systemic inflammatory response Martin Westerberg, MD, Anders.

Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity Cedric Manlhiot, PhD, Colleen.

Activated coagulation during open and endovascular abdominal aortic aneurysm repair Lars Englberger, MD, Hannu Savolainen, MD, PhD, Peter Jandus, Matthias.

Infant cardiopulmonary bypass: a procoagulant state

Bradford B. Smith, MD, Matthew A

Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery Christian.

Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery Julio C Vasquez, MD, Anna Vichiendilokkul, PharmD, Syed Mahmood, MD,

Individualized heparin and protamine management in infants and children undergoing cardiac operations Massimiliano Codispoti, MD, Christopher A Ludlam,

Early and Midterm Results of Off-Pump Coronary Artery Bypass Grafting

Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary.

Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass Nobuhiko Hayashida, MD, PhD, Hiroshi Tomoeda, MD, Takeshi Oda, MD,

No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits Christian Olsson, MD, Agneta Siegbahn, MD, PhD,

Ronald A. Bronicki, MD, Carl L. Backer, MD, Harris P

Is the kaolin or celite activated clotting time affected by tranexamic acid? J.F.Matthias Bechtel, MD, Joachim Prosch, Hans-Hinrich Sievers, MD, Claus.

Assembly and Deployment of a Branched Arch Stent Graft Using the Transaortic Approach Toshihiko Shibata, MD, Hidekazu Hirai, MD, Toshihiro Fukui, MD,

Stephanie B. Clayton, PharmD, Jeffrey R. Acsell, CCP, Arthur J

Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair Greg Stratmann, MD, PhD, Isobel A Russell,

The role of antithrombin III in the perioperative management of the patient with unstable angina Marco Rossi, MD, Lorenzo Martinelli, MD, Sergio Storti,

Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost Michael J Ray, PhD, Mark F O’Brien

Tricuspid Valve Repair of Idiopathic Papillary Muscle Rupture

Effect of Nitric Oxide Gas on Platelets During Open Heart Operations

Fraser D. Rubens, MD, MS, Gilbert Lavalee, Marc A

Neointimal formation at the sites of anastomosis of the internal thoracic artery grafts after coronary artery bypass grafting in human subjects: An immunohistochemical.

Comparison of Blood Activation in the Wound, Active Vent, and Cardiopulmonary Bypass Circuit Olivier Fabre, MD, PhD, André Vincentelli, MD, PhD, Delphine.

Advances in the heart-lung machine after John and Mary Gibbon

The Brain Uses Mostly Dissolved Oxygen During Profoundly Hypothermic Cardiopulmonary Bypass Franklin Dexter, MD, PhD, Frank H Kern, MD, Bradley J Hindman,

Conduction disturbances after superior septal approach for mitral valve repair Yoshio Misawa, MD, PhD, Katsuo Fuse, MD, Koji Kawahito, MD, Tsutomu Saito,

Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient

Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations Martin Misfeld, MD, Sven Dubbert, Sawas Eleftheriadis,

An Assay to Monitor Bivalirudin Levels on Cardiopulmonary Bypass

Influence of High- and Low-Dose Aprotinin on Activation of Hemostasis in Open Heart Operations Wulf Dietrich, Karl Schöpf, Michael Spannagl, Marianne.

Balance of proinflammatory and antiinflammatory cytokines at thoracic cancer operation Darryl M Atwell, MD, Katherine P Grichnik, MD, Mark F Newman, MD,

Karl A. Bocchieri, BS, CCP, S. Jacob Scheinerman, MD, L

A randomized trial of antithrombin concentrate for treatment of heparin resistance Mathew R Williams, MD, Alyssa B D’Ambra, BA, James R Beck, Talia B.

Thrombophilic Variables Do Not Increase the Generation or Procoagulant Activity of Thrombin During Cardiopulmonary Bypass Peter Raivio, MD, Jari Petäjä,

Intravenous milrinone in cardiac surgery

High-Dose ϵ-Aminocaproic Acid Versus Aprotinin: Antifibrinolytic Efficacy in First-Time Coronary Operations Balthasar Eberle, Eckhard Mayer, Gerhard.

Hemostasis Alterations in Patients With Acute Aortic Dissection

Presentation transcript:

Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization Hiroshi Kumano, MD, PhD, Shigefumi Suehiro, MD, PhD, Koji Hattori, MD, PhD, Toshihiko Shibata, MD, PhD, Yasuyuki Sasaki, MD, Mitsuharu Hosono, MD, Hiroaki Kinoshita, MD, PhD The Annals of Thoracic Surgery Volume 68, Issue 4, Pages 1252-1256 (October 1999) DOI: 10.1016/S0003-4975(99)00697-9

Fig 1 Activated clotting time (ACT, mean ± standard deviation). Closed circles indicate the high-dose (H) group and open circles the low-dose (L) group. Samples were obtained at the following time points: before induction of anesthesia (Bef); 5 minutes after heparin administration (Hep); 10, 60, and 90 minutes after the initiation of cardiopulmonary bypass (10m, 60m, and 90m); 5 minutes after protamine administration (Pro); and 1, 3, 6, 12, and 24 hours after the termination of cardiopulmonary bypass (1h, 3h, 6h, 12h, and 24h). Significant differences between the two groups were observed during systemic heparinization (∗p < 0.01 versus the low-dose group.) The Annals of Thoracic Surgery 1999 68, 1252-1256DOI: (10.1016/S0003-4975(99)00697-9)

Fig 2 Plasma concentration of thrombin-antithrombin complex (TAT, mean ± standard deviation). Abbreviations and other legends are the same as in Figure 1. There were no significant differences between the two groups at any time point. The Annals of Thoracic Surgery 1999 68, 1252-1256DOI: (10.1016/S0003-4975(99)00697-9)

Fig 3 Plasma concentration of fibrinopeptide A (FPA, mean ± standard deviation). Abbreviations and other legends are the same as in Figure 1. There were no significant differences between the two groups at any time point. The Annals of Thoracic Surgery 1999 68, 1252-1256DOI: (10.1016/S0003-4975(99)00697-9)

Fig 4 Plasma concentration of plasmin-alpha 2 plasmin inhibitor complex (PIC, mean ± standard deviation). Abbreviations and other legends are the same as in Figure 1. There were no significant differences between the two groups at any time point. The Annals of Thoracic Surgery 1999 68, 1252-1256DOI: (10.1016/S0003-4975(99)00697-9)

Fig 5 Plasma concentration of d-dimer (mean ± standard deviation). Abbreviations and other legends are the same as in Figure 1. There were no significant differences between the two groups at any time point. The Annals of Thoracic Surgery 1999 68, 1252-1256DOI: (10.1016/S0003-4975(99)00697-9)